Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BMRN, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA | Options-implied move |
|---|---|---|---|---|---|
| 2027-02-28 | VOXZOGO | children with achondroplasia | NDA | 66% | ±20% by Apr 16 |
| 2027-05-30 | VOXZOGO | hypochondroplasia (HCH) | NDA | 66% | – |
Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Sapropterin FDA approved Dec 2007 · Kuvan |
GTP Cyclohydrolase Deficiency | Phase 1/2 · NCT01425528 | Completed |
| Pegvaliase-Pqpz FDA approved May 2018 · Palynziq |
Phenylketonuria | Phase 4 · NCT07477691 | Recruiting |
| Vosoritide FDA approved Nov 2021 · Voxzogo |
Achondroplasia | Phase 3 · NCT03424018 | Active not recruiting |
| Cerliponase Alfa FDA approved Apr 2017 · Brineura |
Jansky-Bielschowsky Disease | Phase 2 · NCT02678689 | Completed |
| Elosulfase Alfa FDA approved Feb 2014 · Vimizim |
Mucopolysaccharidosis IV A | N/A · NCT03204370 | Completed |
| RDD to Palynziq | Phenylketonuria | Phase 4 · NCT06780332 | Completed |
| Vosoritide Injection [Voxzogo] | Achondroplasia | Phase 2/3 · NCT07441876 | Recruiting |
| Valoctocogene Roxaparvovec | Hemophilia A | Phase 3 · NCT06224907 | Active not recruiting |
| INZ-701 | Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency | Phase 3 · NCT06046820 | Terminated |
| Control | Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency | Phase 3 · NCT06046820 | Terminated |
| BMN 333 | Achondroplasia | Phase 2/3 · NCT07441876 | Recruiting |
| BMN 307 | Phenylketonuria (PKU) | Phase 1/2 · NCT04480567 | Active not recruiting |
| BMN 351 | Duchenne Muscular Dystrophy | Phase 1/2 · NCT06280209 | Active not recruiting |
| Human Growth Hormone | Idiopathic Short Stature | Phase 2 · NCT06382155 | Recruiting |
| BMN 349 | Alpha 1-Antitrypsin Deficiency | Phase 1 · NCT06738017 | Active not recruiting |
| L-Ascorbate | Claudication, Intermittent | Phase 1 · NCT04800692 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not BMRN's own candidates): Methotrexate, L-Arginine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BMRN holds $1.5B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 8 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BMRN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 19,373,309 | 10.00% | 2026-10-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 10,113,219 | 5.22% | 2026-03-31 |
| Alexander Hardy Chief Executive Officer, Director · +89,200 options |
Insider | 214,635 | 0.11% | 2026-03-17 |
| Richard A Meier Director |
Insider | 126,926 | 0.07% | 2025-12-31 |
| Brian Mueller EVP, Chief Financial Officer · +44,600 options |
Insider | 123,314 | 0.06% | 2026-03-17 |
| Charles Greg Guyer EVP, Chief Technical Officer · +35,680 options |
Insider | 84,140 | 0.04% | 2026-03-17 |
| George Eric Davis EVP, Chief Legal Officer · +34,690 options |
Insider | 61,003 | 0.03% | 2026-09-02 |
| Robert J. Hombach Director |
Insider | 49,360 | 0.03% | 2026-06-02 |
| Gregory R Friberg EVP, Chief R&D Officer · +45,600 options |
Insider | 47,732 | 0.02% | 2026-09-30 |
| Willard H Dere Director |
Insider | 46,440 | 0.02% | 2026-06-02 |
| Cristin Hubbard EVP, Chief Commercial Officer · +36,680 options |
Insider | 42,472 | 0.02% | 2026-05-20 |
| Elizabeth M Anderson Director |
Insider | 41,940 | 0.02% | 2026-06-02 |
Share count 193,694,734 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BMRN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →